Glen Eagle Advisors, LLC Roivant Sciences Ltd. Transaction History
Glen Eagle Advisors, LLC
- $593 Billion
- Q3 2024
A detailed history of Glen Eagle Advisors, LLC transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Glen Eagle Advisors, LLC holds 435 shares of ROIV stock, worth $5,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
435Holding current value
$5,450% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ROIV
# of Institutions
311Shares Held
508MCall Options Held
1.26MPut Options Held
2.52M-
Sb Investment Advisers (Uk) LTD London, X065.9MShares$826 Million6.27% of portfolio
-
Qvt Financial LP New York, NY65.8MShares$824 Million73.2% of portfolio
-
Viking Global Investors LP54.1MShares$678 Million2.42% of portfolio
-
Vanguard Group Inc Valley Forge, PA41.7MShares$522 Million0.01% of portfolio
-
Black Rock Inc. New York, NY35.4MShares$443 Million0.01% of portfolio
About Roivant Sciences Ltd.
- Ticker ROIV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 704,382,976
- Market Cap $8.83B
- Description
- Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...